Previous researches have demonstrated that QFY improves cognitive function in AD models through mechanisms such as activating the Keap1/Nrf2/ARE signaling pathway (97), inhibiting the RAGE/NF-κB pathway (98), modulating gut microbiota (62), and regulating immune responses (63). The gene discussed is KEAP1; the disease is Alzheimer disease.